Unlock the Editor’s Digest totally free
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
Eli Lilly, the world’s largest drugmaker by market worth, is in superior talks to purchase cancer-focused biotech Scorpion Therapeutics in a deal value as much as $2.5bn, in keeping with individuals near the discussions.
Eli Lilly’s pursuit of privately owned Scorpion is the most recent instance of its technique of redistributing the massive windfall from its blockbuster diabetes and weight problems medicine Mounjaro and Zepbound into diversifying its pipeline.
As a part of the proposed phrases, Eli Lilly would pay Boston-based Scorpion about $1bn up entrance adopted by as much as $1.5bn at a later date if sure efficiency milestones have been met, in keeping with three individuals accustomed to the small print.
A deal was more likely to be clinched within the coming days forward of the annual JPMorgan healthcare convention in San Francisco however was not assured, the individuals added. Eli Lilly is being suggested by JPMorgan.
Eli Lilly and JPMorgan declined to remark. Scorpion didn’t reply to requests for remark.
Scorpion’s lead drug inhibits a protein mutation that may be a main driver of breast, gynaecological and head and neck cancers, affecting up 166,000 individuals every year within the US.
Current medicine that concentrate on this protein are related to a excessive diploma of uncomfortable side effects, which Scorpion believes its drugs will cut back. Its candidate drug is presently in phase-two scientific trials.
Scorpion’s founders embrace most cancers knowledgeable Keith Flaherty, the director of scientific analysis at Massachusetts Basic Hospital Most cancers Heart. Flaherty was a co-founder of Loxo Oncology, which was purchased by Eli Lilly for $8bn in 2019.
Loxo Oncology grew to become the centrepiece of Eli Lilly’s oncology technique, nevertheless, the pharma group has additionally made a number of bolt-on acquisitions extra just lately.
In 2023, it paid $1.3bn for radiopharmaceutical biotech Level BioPharma, whereas final yr it agreed partnerships with cancer-focused biotechs Aktis Oncology and Radionetics.
Advisers and opponents have been watching how Eli Lilly spends its revenues from its anti-obesity medicines: to this point it has principally opted for smaller offers. It has additionally spent a lot of its money circulation on increasing its manufacturing capability for its weight reduction medicine.
Eli Lilly’s market capitalisation was simply over $750bn as of early Friday afternoon in New York.
It’s anticipated to generate about $46bn in gross sales this yr, a lot of this from Mounjaro and Zepbound. Analysts venture that the entire marketplace for weight-loss medicine might be value as much as $130bn in peak annual gross sales.
Eli Lilly chief government Dave Ricks informed the Monetary Instances in September: “We’ve been very profitable with early, tuck-in offers . . . we are able to do extra of that.”
Scorpion has raised $420mn from buyers together with enterprise capital corporations Lightspeed Enterprise Companions, Constancy Administration and Wellington Administration, in keeping with knowledge supplier PitchBook, and was most just lately valued at $845mn.
If the deal goes by way of, it is going to be the most recent instance of a bolt-acquisition within the run-up to the JPMorgan healthcare convention. Biogen on Friday went public with a $469mn unsolicited bid for biotech Sage Therapeutics, which has an permitted drug for post-partum despair. The FT additionally reported this week that UK drugmaker GSK was nearing an as much as $1bn deal for most cancers biotech IDRx.
